Aurobindo Pharma’s unit IV gets a reprieve; focus on new filings

- The US business has been scaling up, with growth largely coming organically. US revenues are up 48% since Q1 FY19
- It is little wonder that despite doubling from its 52-week lows, the Aurobindo Pharma stock is still 23% lower compared to its 52-week high last April